Read news on sofetabart mipitecan with our app.
Read more in the app
First patient enrolled in GOG-3133/ FRAmework-01 phase 3 study evaluating sofetabart mipitecan (LY4170156), a novel ADC targeting folate receptor alpha (FRĪ±), in recurrent ovarian cancer - EurekAlert!
